Aradigm Corp. (ARDM) Misses Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Aradigm Corp. (ARDM) Announces Approval of EMA Request to Review Pulmaquin
March 17, 2016 7:09 AM EDTAradigm Corporation (Nasdaq: ARDM) announced that the European Medicines Agency (EMA) has approved its request to review Pulmaquin, Aradigms investigational inhaled liposomal ciprofloxacin product, under the Centralised Authorisation Procedure drug review process. This procedure results in a single marketing authorization that is valid... More
